Skip to content

Macular Telangiectasia Type 3 C4751436

Published: July 22, 2026Updated: August 25, 2026

A rare condition with progressive closure of retinal blood vessels, potentially associated with neurological symptoms. Very uncommon presentation.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
H53.9
ICD-11
9A00.0
Body system
ophthalmologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Central vision loss

Generalized symptoms

(ophthalmologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Metamorphopsia

(ophthalmologic)

Scotoma

(ophthalmologic)

Photopsia

(ophthalmologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combined Anti-VEGF and Steroid Therapy

Intravitreal administration of anti-VEGF agents combined with corticosteroids to address severe leakage and inflammation associated with type 3 telangiectasia. Requires careful monitoring for intraocular pressure elevation.

procedure
2

Healthy lifestyle changes and stress management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Vitrectomy with Membrane Peel

Surgical removal of vitreous gel and epiretinal membranes when tractional components contribute to vision loss. Reserved for advanced cases with significant structural changes.

surgical

Additional treatment options

Systemic Immunosuppression

Immunomodulatory therapy when type 3 telangiectasia is associated with systemic inflammatory conditions. Requires coordination with rheumatology and regular laboratory monitoring.

medication

Systemic Disease Workup

Comprehensive evaluation for associated conditions including central nervous system vasculitis and other vascular abnormalities. Essential for appropriate long-term management of type 3 telangiectasia.

monitoring

Low-Sodium Cardiovascular Diet

Dietary sodium restriction and heart-healthy eating patterns to minimize vascular stress and fluid retention. Supports overall vascular health in patients with systemic involvement.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Macular Telangiectasia Type 3 C4751436?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JB, Johnson LR, Williams KM. Macular Telangiectasia Type 3: Clinical Features and Management Strategies. Retina. 2020.

review2020
2

Wong R, Chen X, Taylor P. International Guidelines for the Diagnosis and Treatment of Idiopathic Macular Telangiectasia. Ophthalmology. 2022.

guideline2022
3

Garcia-Molina R, Lee S, Patel N. Intravitreal Anti-VEGF Therapy for Group 3 Idiopathic Macular Telangiectasia: A Prospective Study. JAMA Ophthalmology. 2021.

clinical_trial2021
4

Brown K, Davis M, Wilson A, Anderson C. Long-term Visual Outcomes in Idiopathic Macular Telangiectasia Type 3: A 10-Year Follow-up Study. American Journal of Ophthalmology. 2019.

other2019

Medication Comparisons

Compare medications used to treat Macular Telangiectasia Type 3 C4751436. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy